JPWO2020146221A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020146221A5 JPWO2020146221A5 JP2021538982A JP2021538982A JPWO2020146221A5 JP WO2020146221 A5 JPWO2020146221 A5 JP WO2020146221A5 JP 2021538982 A JP2021538982 A JP 2021538982A JP 2021538982 A JP2021538982 A JP 2021538982A JP WO2020146221 A5 JPWO2020146221 A5 JP WO2020146221A5
- Authority
- JP
- Japan
- Prior art keywords
- binding domain
- antigen binding
- polypeptide
- domain binds
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 89
- 102000036639 antigens Human genes 0.000 claims 89
- 108091007433 antigens Proteins 0.000 claims 89
- 108090000765 processed proteins & peptides Proteins 0.000 claims 59
- 229920001184 polypeptide Polymers 0.000 claims 57
- 102000004196 processed proteins & peptides Human genes 0.000 claims 57
- 238000006467 substitution reaction Methods 0.000 claims 27
- 108010002350 Interleukin-2 Proteins 0.000 claims 22
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 21
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 21
- 150000001413 amino acids Chemical group 0.000 claims 20
- 210000001744 T-lymphocyte Anatomy 0.000 claims 11
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 10
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 9
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 8
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 claims 6
- 101150064015 FAS gene Proteins 0.000 claims 6
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 claims 6
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 5
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 5
- 102220503468 Superoxide dismutase [Cu-Zn]_D84S_mutation Human genes 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 102220638990 Beta-enolase_H16A_mutation Human genes 0.000 claims 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 4
- 101150069255 KLRC1 gene Proteins 0.000 claims 4
- -1 Kabat amino acids Chemical class 0.000 claims 4
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims 4
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 210000000822 natural killer cell Anatomy 0.000 claims 4
- 102220096696 rs62625272 Human genes 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 3
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 3
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims 3
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 3
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 3
- 102000017578 LAG3 Human genes 0.000 claims 3
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 3
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 3
- 230000001093 anti-cancer Effects 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102200100726 rs61752874 Human genes 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims 2
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims 2
- 102220498123 Protein LRATD2_E95S_mutation Human genes 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 2
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 2
- 229960000074 biopharmaceutical Drugs 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 239000004308 thiabendazole Substances 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 102220638986 Beta-enolase_H16S_mutation Human genes 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100038078 CD276 antigen Human genes 0.000 claims 1
- 208000009458 Carcinoma in Situ Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 102220603939 Clathrin heavy chain 1_P65N_mutation Human genes 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 108700004922 F42A Proteins 0.000 claims 1
- 102220606752 Gap junction beta-1 protein_H16P_mutation Human genes 0.000 claims 1
- 101150112082 Gpnmb gene Proteins 0.000 claims 1
- 102100035943 HERV-H LTR-associating protein 2 Human genes 0.000 claims 1
- 101150046249 Havcr2 gene Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001021491 Homo sapiens HERV-H LTR-associating protein 2 Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- 102220604965 Killer cell immunoglobulin-like receptor 3DL1_M23V_mutation Human genes 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 102220608429 Mitogen-activated protein kinase kinase kinase kinase 1_E95V_mutation Human genes 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102220505697 Palmitoyl-protein thioesterase 1_Y45F_mutation Human genes 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102220495631 Putative uncharacterized protein LOC645739_F42A_mutation Human genes 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 102220503469 Superoxide dismutase [Cu-Zn]_D84A_mutation Human genes 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 102220610852 Thialysine N-epsilon-acetyltransferase_L72G_mutation Human genes 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 claims 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 201000000220 brain stem cancer Diseases 0.000 claims 1
- 102220359607 c.194C>A Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000010918 connective tissue cancer Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000016847 malignant urinary system neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 244000309459 oncolytic virus Species 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 201000002628 peritoneum cancer Diseases 0.000 claims 1
- 230000004962 physiological condition Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000003439 radiotherapeutic effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 201000007048 respiratory system cancer Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 102220234588 rs1114167484 Human genes 0.000 claims 1
- 102200000390 rs121917859 Human genes 0.000 claims 1
- 102220308083 rs1462326368 Human genes 0.000 claims 1
- 102200150061 rs1553765909 Human genes 0.000 claims 1
- 102200105319 rs397514675 Human genes 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 229950005972 urelumab Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 201000004435 urinary system cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 229950003520 utomilumab Drugs 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024185692A JP2025013911A (ja) | 2019-01-07 | 2024-10-22 | 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789075P | 2019-01-07 | 2019-01-07 | |
| US62/789,075 | 2019-01-07 | ||
| PCT/US2020/012296 WO2020146221A1 (en) | 2019-01-07 | 2020-01-06 | Polypeptides comprising modified il-2 polypeptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024185692A Division JP2025013911A (ja) | 2019-01-07 | 2024-10-22 | 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022516557A JP2022516557A (ja) | 2022-02-28 |
| JPWO2020146221A5 true JPWO2020146221A5 (enExample) | 2023-01-19 |
| JP7594161B2 JP7594161B2 (ja) | 2024-12-04 |
Family
ID=69374426
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538982A Active JP7594161B2 (ja) | 2019-01-07 | 2020-01-06 | 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用 |
| JP2024185692A Pending JP2025013911A (ja) | 2019-01-07 | 2024-10-22 | 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024185692A Pending JP2025013911A (ja) | 2019-01-07 | 2024-10-22 | 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220089667A1 (enExample) |
| EP (1) | EP3908596A1 (enExample) |
| JP (2) | JP7594161B2 (enExample) |
| KR (1) | KR20210113265A (enExample) |
| CN (1) | CN113924311A (enExample) |
| AR (1) | AR117770A1 (enExample) |
| AU (1) | AU2020206672B2 (enExample) |
| BR (1) | BR112021012294A2 (enExample) |
| CA (1) | CA3125529A1 (enExample) |
| CL (1) | CL2021001779A1 (enExample) |
| IL (1) | IL284633A (enExample) |
| MX (1) | MX2021008147A (enExample) |
| SG (1) | SG11202106700WA (enExample) |
| TW (1) | TWI874345B (enExample) |
| WO (1) | WO2020146221A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200181220A1 (en) | 2017-08-03 | 2020-06-11 | Synthorx, Inc. | Cytokine conjugates for the treatment of proliferative and infectious diseases |
| EP3746095A4 (en) | 2018-02-01 | 2021-04-21 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
| MA54195A (fr) | 2018-11-08 | 2022-02-16 | Synthorx Inc | Conjugués d'interleukine 10 et leurs utilisations |
| CN114555632A (zh) | 2019-08-23 | 2022-05-27 | 新索思股份有限公司 | Il-15缀合物及其用途 |
| CA3150082A1 (en) | 2019-09-10 | 2021-03-18 | Jerod PTACIN | Il-2 conjugates and methods of use to treat autoimmune diseases |
| KR102313505B1 (ko) * | 2020-06-30 | 2021-10-18 | (주)지아이이노베이션 | 항-lag-3 항체 및 il-2를 포함하는 융합단백질 및 이의 용도 |
| AR122863A1 (es) * | 2020-07-02 | 2022-10-12 | Inhibrx Inc | Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos |
| IL302276A (en) | 2020-10-23 | 2023-06-01 | Asher Biotherapeutics Inc | Fusions with cd8 antigen binding molecules for modulating immune cell function |
| WO2022099090A1 (en) * | 2020-11-06 | 2022-05-12 | Xencor, Inc. | Heterodimeric antibodies that bind tgfbrii |
| EP4251187A4 (en) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | TUMOR-SPECIFIC CLASSIBLE LINKERS |
| CN112979782B (zh) * | 2021-03-08 | 2023-07-18 | 深圳市乐土生物医药有限公司 | 一种多肽及其用途 |
| EP4314033A4 (en) * | 2021-03-31 | 2025-04-23 | Anwita Biosciences, Inc. | FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS |
| TW202321283A (zh) * | 2021-07-20 | 2023-06-01 | 美商英伊布里克斯公司 | Cd8結合多肽及其用途 |
| TW202309102A (zh) * | 2021-07-20 | 2023-03-01 | 美商英伊布里克斯公司 | 靶向cd8之經修飾il-2多肽及其用途 |
| TW202328171A (zh) * | 2021-08-30 | 2023-07-16 | 美商英伊布里克斯公司 | 靶向NKp46之經修飾之IL-2多肽及其用途 |
| US20250136681A1 (en) * | 2021-08-30 | 2025-05-01 | Inhibrx Biosciences, Inc. | NKp46-Binding Polypeptides and Uses Thereof |
| WO2023046156A1 (en) * | 2021-09-26 | 2023-03-30 | Wuxi Biologics (Shanghai) Co. Ltd. | Il-2 variants and fusion proteins thereof |
| TW202334193A (zh) * | 2022-01-05 | 2023-09-01 | 美商英伊布里克斯公司 | 靶向γδ T細胞之經修飾IL-2多肽及其用途 |
| WO2024026449A2 (en) * | 2022-07-28 | 2024-02-01 | Proviva Therapeutics (Hong Kong) Limited | Il-2 procytokine antibody fusion proteins |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| JP4460155B2 (ja) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | マウス抗体のヒト化 |
| PT1454138E (pt) * | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| HUE033349T2 (en) | 2003-10-22 | 2017-11-28 | Keck Graduate Inst | Procedures for the Synthesis of Heteromultimer Polypeptides in Yeast Using an Hagloid Mating Strategy |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| AU2005227263A1 (en) * | 2004-03-05 | 2005-10-06 | Novartis Vaccines And Diagnostics, Inc. | In vitro test system for predicting patient tolerability of therapeutic agents |
| CA2561686C (en) | 2004-03-31 | 2014-12-02 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| CN102101885B (zh) * | 2010-09-01 | 2013-06-05 | 南京发士达生物科技有限公司 | 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途 |
| LT3075745T (lt) * | 2011-02-10 | 2018-11-26 | Roche Glycart Ag | Mutavę interleukino-2 polipeptidai |
| US20150166654A1 (en) * | 2012-05-30 | 2015-06-18 | Chugai Seiyaku Kabushiki Kaisha | Target tissue-specific antigen-binding molecule |
| PE20161324A1 (es) * | 2014-02-06 | 2016-11-25 | Hoffmann La Roche | Proteinas de fusion de interleucina-2 y usos de las mismas |
| CN108884157A (zh) * | 2016-01-11 | 2018-11-23 | 苏黎世大学 | 包含针对白介素2的超级激动剂抗体和检查点阻断剂的组合疗法 |
| KR20240115933A (ko) * | 2016-05-04 | 2024-07-26 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| EP3596118B1 (en) * | 2017-03-15 | 2024-08-21 | Cue Biopharma, Inc. | Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer |
| WO2018184965A1 (en) * | 2017-04-03 | 2018-10-11 | F. Hoffmann-La Roche Ag | Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody |
| CN116375876A (zh) * | 2017-04-05 | 2023-07-04 | 豪夫迈·罗氏有限公司 | 特异性结合pd1和lag3的双特异性抗体 |
| MX2019013517A (es) * | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| EP3641814A4 (en) * | 2017-06-19 | 2021-06-23 | Medicenna Therapeutics Inc. | USES AND METHODS FOR IL-2 SUPERAGONISTS AND AGONISTS AND FUSIONS THEREOF |
-
2020
- 2020-01-06 AU AU2020206672A patent/AU2020206672B2/en active Active
- 2020-01-06 BR BR112021012294-0A patent/BR112021012294A2/pt unknown
- 2020-01-06 JP JP2021538982A patent/JP7594161B2/ja active Active
- 2020-01-06 TW TW109100336A patent/TWI874345B/zh active
- 2020-01-06 EP EP20702547.9A patent/EP3908596A1/en active Pending
- 2020-01-06 CA CA3125529A patent/CA3125529A1/en active Pending
- 2020-01-06 AR ARP200100028A patent/AR117770A1/es unknown
- 2020-01-06 KR KR1020217024431A patent/KR20210113265A/ko active Pending
- 2020-01-06 CN CN202080018011.6A patent/CN113924311A/zh active Pending
- 2020-01-06 US US17/418,458 patent/US20220089667A1/en active Pending
- 2020-01-06 MX MX2021008147A patent/MX2021008147A/es unknown
- 2020-01-06 SG SG11202106700WA patent/SG11202106700WA/en unknown
- 2020-01-06 WO PCT/US2020/012296 patent/WO2020146221A1/en not_active Ceased
-
2021
- 2021-07-05 IL IL284633A patent/IL284633A/en unknown
- 2021-07-05 CL CL2021001779A patent/CL2021001779A1/es unknown
-
2024
- 2024-10-22 JP JP2024185692A patent/JP2025013911A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020146221A5 (enExample) | ||
| US11952421B2 (en) | Bispecific antibodies against CD3EPSILON and ROR1 | |
| JP5851419B2 (ja) | ヘテロダイマー結合タンパク質およびその使用 | |
| Chen et al. | Bispecific antibodies in cancer immunotherapy | |
| Godar et al. | Therapeutic bispecific antibody formats: a patent applications review (1994-2017) | |
| JP2021098732A5 (enExample) | ||
| Müller et al. | Bispecific antibodies | |
| FI3749346T3 (fi) | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät | |
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2022551081A (ja) | 癌処置のための多重特異性結合タンパク質 | |
| CN109796532B (zh) | 靶向成纤维激活蛋白α的结合单元及其应用 | |
| US20240262913A1 (en) | Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies | |
| US20220089722A1 (en) | Heterodimeric fusion protein | |
| CN115066274A (zh) | 三价结合分子 | |
| Spasevska | An outlook on bispecific antibodies: Methods of production and therapeutic benefits | |
| CN115836084A (zh) | 多特异性免疫调节剂 | |
| US20180371088A1 (en) | TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT AND USES THEREOF IN CANCER THERAPY | |
| WO2022095801A1 (zh) | 靶向lir1的抗体及其用途 | |
| JPWO2022006380A5 (enExample) | ||
| Ko et al. | Engineering antibodies for dual specificity and enhanced potency | |
| WO2023147331A1 (en) | Bispecific molecule with tunable affinity to a targetted antigen | |
| RU2021123226A (ru) | Полипептиды, содержащие модифицированный полипептид il-2, и их применения | |
| US20250376524A1 (en) | Tetravalent multispecific binding molecules and methods of use thereof | |
| WO2025201240A1 (en) | Antibodies targeting cd3, cd28, and pd-l1 and uses thereof | |
| WO2025167357A1 (zh) | Cd80/taa融合蛋白相关的肿瘤靶向、t细胞激活分子形式及其应用 |